Neurizon Completes OLE Study for NUZ-001, Shows Significant Survival Benefit in ALS Patients

Neurizon Therapeutics (ASX: NUZ) has announced the successful completion of its Open-Label Extension (OLE) study for NUZ-001 in ALS patients, with the last participant completing 12 months of treatment. NUZ-001, administered at 10 mg/kg daily, was well-tolerated and demonstrated a substantial survival benefit compared to untreated controls from the PRO-ACT historical database. Notably, the treatment reduced the risk of death by 78.5% and significantly extended life expectancy, with some patients now in their 31st month of treatment.

Survival analysis conducted by Berry Consultants showed statistically significant improvements across multiple datasets, with no serious adverse events reported. Out of the original 12 patients from the MEND Phase 1 study, seven remain alive, and six continue receiving NUZ-001 under compassionate use. Top-line results from the OLE study are expected in Q3 2025. These findings strengthen confidence in the upcoming Phase 2/3 HEALEY ALS Platform Trial and highlight NUZ-001's potential as a game-changing ALS therapy.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com